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Abstract
The development of antiretroviral therapy has led to a major reduction in human immunodeﬁciency virus (HIV)-related mortality. There
are now six antiretroviral drug classes, with more than 20 unique antiretroviral drugs. However, HIV drug resistance occurs with all
antiretroviral agents. Drug resistance can affect the response to antiretroviral therapy and is associated with increased mortality. The
emergence of resistance in persons on antiretroviral therapy and the transmission of drug-resistant HIV strains to newly infected per-
sons are now major public health concerns. Resistant variants that make up as little as 1% of the viral population in an HIV-infected per-
son are clinically important, as they can rapidly grow under drug selection pressure and lead to therapy failure. However, current
resistance assays used in the clinic reliably detect resistant variants only if they make up at least 20% of the circulating viral population.
Recently, antiretroviral drugs have been developed that can inhibit HIV replication at new sites within the viral life cycle. These
new drugs may improve clinical outcomes in persons infected with multidrug-resistant HIV. This review addresses the epidemiology and
biological mechanisms of HIV drug resistance and the new approaches to detect and combat HIV drug resistance.
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Introduction
Death rates due to human immunodeﬁciency virus (HIV)
have markedly decreased in regions of the world that have
full access to antiretroviral drugs. Currently, there are six
classes of antiretroviral drugs that inhibit HIV replication at
multiple different sites in the viral life cycle [1]. However,
in the face of this advance, there is concern about the
development and transmission of drug-resistant HIV strains.
HIV drug resistance occurs with every antiretroviral
agent. The development of resistance limits the efﬁcacy of
all antiretroviral drugs [2,3]. Drug resistance can lead to
treatment failure and is associated with increased mortality
[4–7]. Therapy for persons infected with multidrug-resistant
HIV can be complicated and often leads to difﬁcult patient
management issues for clinicians. Furthermore, HIV-infected
persons with resistant strains have been shown to continue
HIV risk behaviours and to transmit resistant strains to
newly infected persons [8]. This article addresses the epide-
miology and biological mechanisms of HIV drug resistance
and the new approaches to detect and treat drug-resistant
HIV strains.
HIV Drug Resistance Dynamics
In an untreated HIV-infected person, approximately ten bil-
lion viruses are produced each day, and 100 million new cells
are infected [9,10]. The poor ﬁdelity of the HIV reverse
transcriptase allows for random mutations with each round
of HIV replication [9]. HIV has a high mutation rate, such
that, theoretically, every possible single-base mutation can
occur within the virus each day [9,10]. These evolutionary
characteristics make HIV highly responsive to selection pres-
sure from drugs that are not fully suppressive of viral replica-
tion. If an antiretroviral regimen does not fully control HIV
replication, drug pressure will lead to the selection and pres-
ervation of viral variants with increasingly reduced drug sus-
ceptibilities [2]. Continued viral replication in the presence
of drug pressure allows for the progressive accumulation of
mutations that can lead to increased resistance [2,11]. Some
antiretrovirals require only a single point mutation to have
high-level drug resistance, whereas others require multiple
point mutations [3,11]. The number of mutations required
to confer resistance contributes to the genetic barrier to
resistance [2,3,11]. Resistant variants in the blood can be
replaced by wild-type populations when drug pressure is not
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present. This results from a reversion to a wild-type viral
genotype from variants with resistance mutations or the out-
growth of wild-type virus from viral reservoir sites (Fig. 1).
However, resistant variants can seed reservoir sites (e.g.
latent infected T-cells) and re-emerge if that drug is used
again (Fig. 1).
Epidemiology and transmission of
drug-resistant HIV strain
The emergence of HIV drug resistance in persons on therapy
and the transmission of resistant HIV strains to newly
infected persons are now major public health problems.
Transmission of drug-resistant HIV to newly infected persons
is a function of the type and the frequency of HIV transmis-
sion risk behaviours, the penetrance of antiretroviral drugs
in a population, the prevalence of drug resistance in those
engaging in risk behaviour, and the stability and transmissibil-
ity of resistant strains.
HIV-infected persons harbouring drug-resistant strains
have been shown to transmit resistant HIV through high-risk
HIV transmission behaviours (unprotected sex or the shar-
ing of needles). Our group investigated the prevalence of
drug resistance in HIV-infected persons under medical care
who continued to engage in high-risk HIV transmission
behaviours [8,12]. Unprotected sexual behaviour was
reported by 45% of HIV-infected sexually active patients at
some point during an approximately 2-year study period. Of
these persons engaging in unprotected sexual events, 31%
had HIV drug resistance at the time of a sexual risk event
(c.13% with multidrug resistance) [13]. As with other sexu-
ally transmitted diseases, there was substantial and complex
variation in the distribution of unprotected sexual events
and in the detection of resistance over time. These data
demonstrated the importance of ongoing risk reduction
strategies for individuals undergoing clinical care for
HIV[13].
Burden of drug resistance in HIV
populations
In one of the largest HIV drug resistance surveys ever per-
formed in the USA, the estimated prevalence of HIV drug
resistance among an adult HIV-positive population that had a
detectable HIV viral load was c.75%, with 48% harbouring
multidrug-resistant strains [14]. This US survey covered a
time period during which many among the infected popula-
tion had been exposed to the inferior, early antiretroviral
regimens commonly used in the mid-1990s. However, many
of these HIV-infected persons may have been able to achieve
viral suppression with newer antiretroviral regimens. Recent
data suggest that the burden of resistance may be declining
in resource-rich countries as newer initial antiretroviral ther-
apy regimens achieve better results [15,16]. It is still sobering
Fig. 1. Illustration of the emergence and archiving of drug-resistant human immunodeﬁciency virus (HIV) variants. A drug-resistant viral strain
that is the dominant variant when drug pressure is present can become a minority (low-abundance) viral variant in the blood when drug
pressure is removed. In this clinical situation, the currently available clinical genotypic resistance assays cannot detect these resistant variants
when they fall below a level of c.20% of the circulating viral population. In an HIV-infected person, if an antiretroviral regimen is used which the
minority viral variant is resistant to, the variant can multiply under the drug pressure and rapidly re-emerge, causing treatment failure. ART,
antiretroviral therapy.
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that the burden of resistance among HIV populations can be
signiﬁcant, and this underscores the importance of the con-
tinued development of new antiretrovirals and new strategies
to treat drug-resistant strains [17 ].
What will be the burden of resistance in resource-poor
countries? Often, in resource-poor countries, the identiﬁca-
tion of a person failing an initial antiretroviral regimen is
based on clinical or immunological monitoring [18]. Viral
load monitoring, which would allow the early capture of viral
escape, is not widely available in these regions, owing to cost
and availability. This inability to detect resistance at an early
stage, thus prolonging the detection of regimen failure, has
raised the concern that more persons may have multiclass-
resistant strains, over time, than if such monitoring were
available.
Non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based regimens are the most commonly used ﬁrst-line ther-
apies in both resource-rich and in resource-poor countries.
The ability to co-formulate three drugs (two nucleoside
reverse transcriptase inhibitors (NRTIs) plus an NNRTI)
into a single pill and the excellent virological response rates
with these combinations have led to their preferred use as
ﬁrst-line therapy in many programmes. Persons failing these
ﬁrst-line antiretroviral regimens can become resistant to a
single class or two classes of antiretrovirals. The likelihood
of developing multidrug-resistant strains depends on the
regimen used and the time for which a person is left on a
failing regimen. In the minority of patients who fail an
NNRTI-based regimen, resistance to both the NNRTI and
nRTI drug classes can occur, resulting in a person harbour-
ing multidrug-resistant strains [7]. It is possible to construct
an antiretroviral salvage regimen in these patients when
there is broad access to other antiretroviral classes [7].
Unfortunately, this is not an option in all regions of the
world. Thus, over time, the burden of resistance in treated
populations in many of the developing countries will proba-
bly increase.
HIV drug resistance in the newly infected
person
The prevalence of drug-resistant strains in newly HIV-
infected persons depends on the survey period and region of
the world investigated. The general estimates are that in the
parts of the world where antiretrovirals have been widely
available for almost 20 years, the rates are approximately
10% (8–15% in the USA and c. 10% in Europe) [17,19,20]. In
other parts of the world where antiretroviral drugs have
been available for only a limited time, the prevalence is
lower, often <5% [21]. Over time, as antiretroviral ‘roll-out’
programmes enroll increasing numbers of HIV-infected indi-
viduals, the likelihood of the transmission of drug-resistant
strains will increase. The WHO recommends that HIV drug
resistance surveillance be part of antiretroviral treatment
programmes [21]. Surveillance for emergent, and transmit-
ted, drug-resistant strains in these populations will help
instruct the programmes and assist in the development of
strategies to prevent the development and transmission of
drug-resistant strains [21].
The transmission of HIV strains that are resistant to ﬁrst-
line therapy options in developing countries may dispropor-
tionately affect these communities. These regions have only
limited options for second-line antiretroviral regimens, as
many new antiretroviral drug classes that have activity
against drug-resistant HIV strains are not readily available,
because funds to purchase these newer agents are lacking.
Thus, the rates of response to salvage antiretroviral regimens
in these regions may not be as robust as those in parts of
the world that have access to the full arsenal of antiretroviral
drug classes.
Detection of HIV drug-resistant strains
It is standard practice to monitor HIV drug resistance
using either genotypic or phenotypic resistance assays. The
use of resistance assays can instruct drug selection, help in
patient management, and improve therapy outcomes [1].
However, a major limitation of commercial resistance assays
is their inability to detect low-abundance resistant variants
that exist as a small portion of the viral population when
there is no antiretroviral drug pressure. Standard resistance
assays used in the clinic reliably detect resistant variants only
if they make up at least 20% of the circulating viral popula-
tion [1]. Recent data from multiple groups suggest that resis-
tant viral variants that make up as little as 1% of the viral
population in a person are clinically important, as they can
rapidly grow under drug selection pressure [22,23]. In these
studies, low-abundance resistant variants were found in both
acutely and chronically infected populations, and the detec-
tion of these previously occult resistant variants predicted
subsequent treatment failure [22,23]. Thus, new resistance
technologies are needed for the clinic to screen for all types
of low-abundance resistant variants. Such assays could have
greater clinical utility, improve patient care, and might prove
valuable in predicting virological responses to new antiretro-
viral regimens. A major area of investigation in the HIV
resistance ﬁeld is how best to improve the existing assays to
achieve this goal.
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Antiretroviral agents to treat
drug-resistant strains
Recently, there have been multiple new antiretroviral agents
approved for use in persons infected with drug-resistant
HIV. Some of these agents have unique mechanisms of action
and inhibit the virus at new sites in the viral life cycle. This
advance has allowed clinicians to construct new regimens for
persons with multidrug-resistant HIV that have resulted in
excellent virological suppression rates [1]. The recently
approved antiretroviral agents include new protease inhibi-
tors (darunavir and tipranavir), an NNRTI with activity
against drug-resistant HIV strains (etravirine), and antiretro-
viral classes that inhibit the virus at new sites of the viral life
cycle, CCR5 inhibitor (maraviroc) and an integrase inhibitor
(raltegravir) (Fig. 2).
The antiretroviral development process has not been syn-
chronous, and the approval of new antiretrovirals was often
spread out over many months to years. This staggered
release of antiretrovirals led to the use of new agents as
functional monotherapy in many patients. New antiretroviral
agents were often added to a failing regimen as clinicians
were pressed to prevent further immunological deterioration
in a person with advanced HIV disease. A single new drug
addition to a failing regimen often led to transient virological
responses with subsequent therapy failure and the develop-
ment of even broader multiclass resistance (resistance to the
recently added antiretroviral agent in addition to the pre-
existing resistance). This clinical practice led to the develop-
ment of multidrug-resistant HIV strains in many persons.
However, the HIV ﬁeld has now reached a point in clinical
care where, if a person develops multidrug-resistant HIV
after initial treatment with an NRTI + NNRTI or NRTI +
PI/r (protease inhibitor boosted by ritonavir)-based regimen,
a clinician can construct a second-line or third-line antiretro-
viral regimen that contains two to three new agents with dif-
ferent mechanisms of activity. These new combinations can
yield excellent results against multidrug-resistant HIV [1].
Hopefully, this new capability will lead to a lower resistance
burden in HIV-infected populations over time (at least in
populations that have full access to all antiretroviral drug
classes). An important issue for the ﬁeld will be to bring
these newer agents to all who are in need, especially in
resource-poor regions, faster than has been done in the
past.
Conclusion
Antiretroviral therapy has dramatically reduced HIV-related
mortality. There is an ongoing rapid scale-up of access to
antiretroviral therapy in the regions of the globe where HIV-
infected populations are in great need. This may lead to the
emergence and transmission of drug-resistant strains of HIV,
an important problem that we have already witnessed in
parts of the world that have had long-standing access to anti-
retrovirals. The transmission of drug-resistant HIV is an
important public health issue in all regions of the world. HIV
drug resistance surveillance programmes (such as the WHO
HIVDR Program) are needed to ensure the efﬁcacy of anti-
retroviral therapy programmes and to help direct the choice
Fig. 2. Antiretroviral classes/drugs and their
site of activity: nucleoside and nucleotide
reverse transcriptase inhibitors (NRTIs); non-
nucleoside reverse transcriptase inhibitors
(NNRTIs); protease inhibitors (PIs); fusion
inhibitor; CCR5 inhibitor; integrase inhibitor;
*pre-integration complex (PIC).
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of drugs and intervention programmes. Furthermore, new
resistance technologies are needed to better monitor low-
abundance drug-resistant HIV variants, as these variants can
lead to treatment failure. The availability of new antiretrovi-
ral drug classes that have activity against drug-resistant
strains should improve the clinical outcomes in those
infected with multidrug-resistant strains of HIV. Global
access to these important new agents will be an important
issue for the ﬁeld.
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